These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37300424)

  • 1. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.
    Zhou P; Li W; Zuo S; Ma R; Yuan X; Zhu Z
    Leuk Lymphoma; 2023; 64(8):1373-1388. PubMed ID: 37300424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.
    Giri S; Huntington SF; Wang R; Zeidan AM; Podoltsev N; Gore SD; Ma X; Gross CP; Davidoff AJ; Neparidze N
    Blood Adv; 2020 May; 4(10):2245-2253. PubMed ID: 32442299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
    Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 1q21 abnormalities in multiple myeloma.
    Schmidt TM; Fonseca R; Usmani SZ
    Blood Cancer J; 2021 Apr; 11(4):83. PubMed ID: 33927196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
    Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
    Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
    [No Abstract]   [Full Text] [Related]  

  • 6. [Research Advances in Multiple Myeloma with Chromosome 1q21 Amplification].
    Wang C; Hu R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):649-652. PubMed ID: 35400366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
    Nahi H; Våtsveen TK; Lund J; Heeg BM; Preiss B; Alici E; Møller MB; Wader KF; Møller HE; Grøseth LA; Østergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
    Eur J Haematol; 2016 Jan; 96(1):46-54. PubMed ID: 25779478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets.
    Burroughs Garcìa J; Eufemiese RA; Storti P; Sammarelli G; Craviotto L; Todaro G; Toscani D; Marchica V; Giuliani N
    Cells; 2021 Jun; 10(6):. PubMed ID: 34205916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
    Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
    Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
    Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M
    Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
    Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.
    Weinhold N; Salwender HJ; Cairns DA; Raab MS; Waldron G; Blau IW; Bertsch U; Hielscher T; Morgan GJ; Jauch A; Davies FE; Hänel M; Cook G; Scheid C; Houlston R; Goldschmidt H; Jackson G; Kaiser MF
    Haematologica; 2021 Oct; 106(10):2754-2758. PubMed ID: 34092058
    [No Abstract]   [Full Text] [Related]  

  • 14. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
    Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
    Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse.
    Mlynarcikova M; Balcarkova J; Mickova P; Scudla V; Pika T; Bacovsky J; Minarik J; Janousova E; Jarosova M
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):358-65. PubMed ID: 27052024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
    Deng P; Zhou YL; Wei YL; Li P; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
    Kastritis E; Migkou M; Dalampira D; Gavriatopoulou M; Fotiou D; Roussou M; Kanellias N; Ntanasis-Stathopoulos I; Malandrakis P; Theodorakakou F; Sevastoudi A; Eleutherakis-Papaiakovou E; Triantafyllou T; Terpos E; Katodritou E; Dimopoulos MA
    Am J Hematol; 2022 Sep; 97(9):1142-1149. PubMed ID: 35731917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prognostic value of 1q21 amplification in multiple myeloma].
    Abramova TV; Obukhova TN; Mendeleeva LP; Pokrovskaya OS; Gribanova EO; Ryzhko VV; Grebenyuk LA; Nareyko MV; Solovyev MV; Votyakova OM; Kulikov SM; Rusinov MA; Savchenko VG
    Ter Arkh; 2017; 89(7):32-38. PubMed ID: 28766538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.